Quarterly ResultMay 13, 2026, 07:11 AM
Xtant Medical Raises 2026 Revenue Guidance to $101-$105M; Q1 Net Loss $3.1M
AI Summary
Xtant Medical Holdings, Inc. reported a Q1 2026 net loss of $3.1 million on revenue of $20.9 million, a decline from Q1 2025 due to asset sales and non-recurring license revenue. Despite the Q1 financial performance, the company significantly strengthened its balance sheet by reducing total indebtedness by $13.3 million. Xtant Medical also announced an exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST® Bellows product and launched Trivium™ Shaped, leading to an increase in full-year 2026 revenue guidance to a range of $101-$105 million.
Key Highlights
- Raised full-year 2026 revenue guidance to $101-$105 million, up from $95-$99 million previously.
- Entered exclusive U.S. distribution agreement for Dilon Technologies HEMOBLAST Bellows, hiring Dilon's 20-person U.S. sales team.
- Q1 2026 total revenue was $20.9 million, down from $32.9 million in Q1 2025, primarily due to asset sale.
- Q1 2026 net loss was $3.1 million, compared to net income of $58,000 for Q1 2025.
- Q1 2026 Non-GAAP adjusted EBITDA loss was $1.6 million, compared to positive $3.0 million in Q1 2025.
- Reduced total indebtedness by $13.3 million in Q1 2026, including $10.4 million from revolving credit and $2.8 million from term loan.
- Launched Trivium Shaped, an extension of its demineralized bone matrix allograft for bone grafting procedures.
- Received the final $10.7 million due from Companion Spine, finalizing the previously announced asset sale.